Granulocyte Colony-Stimulating Factor Activating HIF-1α Acts Synergistically with Erythropoietin to Promote Tissue Plasticity

Shih-Ping Liu1,2, Shin-Da Lee3,4, Hsu-Tung Lee5, Demeral David Liu6, Hsiao-Jung Wang1, Ren-Shyan Liu7, Shinn-Zong Lin1,8, Woei-Cherng Shyu1,8*

1 Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan, 2 Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, 3 Department of Physical Therapy, Graduate Institute of Rehabilitation Science, China Medical University, Taichung, Taiwan, 4 Department of Healthcare Administration, Asia University, Taichung, Taiwan, 5 Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan, 6 Department of Dentistry, China Medical University Hospital, Taichung, Taiwan, 7 Department of Nuclear Medicine, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, 8 Graduate Institute of Immunology, China Medical University, Taichung, Taiwan

Abstract

Stroke and peripheral limb ischemia are serious clinical problems with poor prognosis and limited treatment. The cytokines erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) have been used to induce endogenous cell repair and angiogenesis. Here, we demonstrated that the combination therapy of EPO and G-CSF exerted synergistic effects on cell survival and functional recovery from cerebral and peripheral limbs ischemia. We observed that even under normoxic conditions, G-CSF activates hypoxia-inducible factor-1α (HIF-1α), which then binds to the EPO promoter and enhances EPO expression. Serum EPO level was significantly increased by G-CSF injection, with the exception of Tg-HIF-1α+/−/−/− mice. The neuroplastic mechanisms exerted by EPO combined with G-CSF included enhanced expression of the antiapoptotic protein of Bcl-2, augmented neurotrophic factors synthesis, and promoted neovascularization. Further, the combination therapy significantly increased homing and differentiation of bone marrow stem cells (BMSCs) and intrinsic neural progenitor cells (INPCs) into the ischemic area. In summary, EPO in combination with G-CSF synergistically angiogenesis and tissue plasticity in ischemic animal models, leading to greater functional recovery than either agent alone.

Introduction

Erythropoietin (EPO), a 30.4 kDa glycoprotein, acts mainly on late erythroid precursor cells to induce maturation. Exogenous administration of EPO and endogenous upregulation of EPO receptors have been demonstrated to promote neuronal survival in the injured brain [1]. EPO has also been identified as an effective neuroprotective agent in neuronal cell cultures [2]. Furthermore, granulocyte-colony stimulating factor (G-CSF) is a 19.6 kDa glycoprotein that has long been used to treat neutropenia [3]. Similar to EPO, G-CSF has also shown neuroprotective potential in animal models of stroke [4,5] and in neuronal cultures [6]. Hypoxia-inducible factor-1α (HIF-1α) is a heterodimeric transcription factor composed of two basic helix-loop-helix (bHLH) proteins of the PAS family, HIF-1α and HIF-1β [7]. Although HIF-1α activation is important in the response to environmental hypoxia by genes encoding vascular endothelial growth factor (VEGF), stromal cell derived factor 1 (SDF-1) and EPO, there is increasing evidence that HIF-1α activation [8] induced by interleukin (IL)-1β and TNF [9], angiotensin II [10], thrombin [11], and insulin [12] also occurs under normoxic conditions. However, to date there have been no reports of G-CSF activating HIF-1α to upregulate EPO expression under normoxic conditions.

Previous reports have described the beneficial effects from exogenous administration of multiple cytokines, such as EPO, G-CSF, stem cell factor (SCF) and IL-11 [13,14,15]. The simultaneous administration of two or three cytokines may result in non-additive, synergistic or inhibitory interactions. EPO combined with G-CSF not only rescued patients suffering from life-threatening neutropenia but also improved blood cell regeneration in patients receiving high-dose chemotherapy [16,17]. However, the neuroplastic and angiogenic effects of combined EPO and G-CSF treatment have not been investigated.

In this study, we intended to demonstrate that G-CSF upregulates EPO expression via the induction of HIF-1α activity, and that the co-treatment of G-CSF and EPO synergistically enhances neural survival and angiogenesis in both primary cortical cultures and animal models of ischemia.
Results

G-CSF Stimulated HIF-1α and EPO Expression

To evaluate whether subcutaneous injection of G-CSF for 5 consecutive days could enhance EPO production in humans, serum EPO levels of human donors (n=24) were measured by ELISA at 1, 3, 7, and 14 days. We noted an increase in serum EPO level, which the peak level was seen in the 3rd days after first G-CSF injection (Fig. 1A).

Next, to examine increased EPO protein expression from HIF-1α activation, human umbilical vein endothelial cells (HUVECs, Cambrex) were treated with G-CSF for different durations (0.5, 1, 4, 10 and 24 hours), and at different concentrations (0.01, 0.1, 1 and 10 µg/mL). HIF-1α and of EPO protein expression increased following G-CSF treatment (Fig. 1B-C). In addition, G-CSF increased HIF-1α activity in whole cell lysate (Fig. 1D). The protein levels of HIF-1α and EPO were blocked by pretreatment with 2-methoxyestradiol (2-ME2, 5 µM; Fig. 1D).

The subcellular location of HIF-1α in HUVECs with or without G-CSF treatment was determined by immunohistochemistry. Without G-CSF treatment, HIF-1α was primarily localized in the cytosol (Fig. 1E). G-CSF treatment induced the translocation of HIF-1α into the nucleus or to perinuclear areas (Fig. 1E). Pretreatment with 2-ME2 in HUVECs for 16 hours blocked the HIF-1α nuclear translocation (Fig. 1E).

According to results from an electrophoretic mobility shift assay (EMSA) using a 18-bp oligonucleotide probe containing the HRE with the HIF-1α-binding site of the EPO gene promoter (Fig. 2A). G-CSF at a concentration of 0.1 µg/mL was sufficient to induce DNA binding complex formation. Binding was reduced by competition with an unlabeled oligonucleotide, and the complexes were supershifted by a specific HIF-1α antibody in a similar manner in reaction to hypoxia, indicating the presence of this protein in these complexes (Fig. 2B). In addition, oxygen glucose deprivation (OGD), G-CSF (0.1 µg/mL), and chemical hypoxic (deferoxamine, DFO) conditions induced higher luciferase reporter gene activity in a construct (pEpoE-luc) containing HRE from the erythropoietin gene coupled to a SV40 promoter than in a mutant (pEpoEm1-luc) construct or control cells (Fig. 2C).

EPO+G-CSF Exerted Survival and Plastic Effects

To examine whether EPO combined with G-CSF exerts a neuroprotective effect through an antiapoptotic pathway, Bcl-2 protein expression, caspase-3 activity and synthesis of neurotrophic factors under OGD were measured in primary cultures of rat cortical cultures (PCCs) with or without co-treatment of EPO and G-CSF. In OGD, PCCs pretreated with EPO+G-CSF for 12 hours showed significantly less caspase-3 activity by fluorimetry than in control cells (Fig. 3A). We noted an increase in serum EPO level, which the peak level was seen in the 3rd days after first G-CSF injection (Fig. 1A).

The results of Western blot analysis and ELISA (each group n=8) with different therapeutic recipes (Fig. 4A) [1,6,16,18,19,20,21]. At 7 d post-cerebral ischemia, infarct volumes were significantly smaller in three groups: EPO (10,000 U/kg) + G-CSF (100 µg/kg) in Group F; EPO (5000 U/kg) + G-CSF (50 µg/kg) in Group G; and EPO (2500 U/kg) + G-CSF (50 µg/kg) in Group I (Fig. 4A). We selected a lower dosage combination group from one of these three groups to investigate the combination therapeutic effect in comparison with those for single agent and saline control. In all, we selected 4 of the 11 groups (each treatment started at one day after cerebral ischemia) for this study: 1) a low-dose combination of EPO (2500 U/kg) + G-CSF (50 µg/kg) (Group I, 2) G-CSF alone (50 µg/kg) (Group C), 3) EPO alone (5000 U/kg) (Group D), and 4) a saline control (Fig. 4B).

Seven days after cerebral ischemia, infarct volume was significantly reduced from an average of 159±32 mm³ in saline-treated controls to 77±26 mm³ in EPO, 71±26 mm³ in G-CSF, and 42±23 mm³ in EPO+G-CSF group (Fig. 4C). The infarct area of the largest infarcted slice decreased significantly from 17.1±5.3 mm² in controls, to 10.1±4.1 mm² in EPO, 9.0±5.2 mm² in G-CSF, and 6.1±3.9 mm² in EPO+G-CSF group (Fig. 4C). The number of infarcted slices also decreased significantly from 7.1±1.8 slices/rat in control animals to 4.8±1.9 slices/rat in EPO-, 4.3±1.4 slices/rat in G-CSF-, and 2.7±1.3 slices/rat in EPO+G-CSF-treated animals (Fig. 4C).

Body asymmetry, locomotor activity tests and grip strength measurement were used to assess the neurological functional recovery in EPO+G-CSF-treated, EPO-treated, G-CSF-treated and control rats (each group n=10). EPO+G-CSF-treated rats showed much higher percentage of recovery in body swing tests than rats treated with EPO only, G-CSF only, or control rats (Fig. 4D). Locomotor activities after cerebral ischemia in EPO+G-CSF group were significantly better than those in the other groups (Fig. 4E, F and G). In addition, the EPO + G-CSF-treated group had a much higher strength than the other groups in terms of forelimb grip strength 28 d post-treatment relative to pre-treatment (Fig. 4H).

To verify whether subcutaneous EPO+G-CSF administration could enhance metabolic activity, we examined cortical glucose metabolism by [18F]fluoro-2-deoxyglucose positron emission tomography (FDG-PET) one week post-treatment (each group n=8). The results indicate that FDG uptake in the right cortices of the EPO + G-CSF group was significantly better than that in the EPO, G-CSF or control groups (Fig. 4I).

Next, we examined the anti-apoptotic effects and neurotrophic factor synthesis of EPO + G-CSF in post-cerebral ischemic rats by Western blot analysis and ELISA (each group n=8). The anti-apoptotic protein Bcl-2 was significantly upregulated in EPO+G-CSF, EPO, and G-CSF groups, compared with control group (Fig. 4J), and the EPO+G-CSF combination induced significantly greater expression of Bcl-2 than EPO or G-CSF alone 24 hr after ischemia (Fig. 4J). One week after ischemia, rat brains treated with EPO+G-CSF had higher BDNF and SDF-1 titers than those treated with EPO alone, G-CSF alone, or control (Fig. 4K).

As measured by ELISA 3 days after G-CSF (250 µg/kg) or EPO (5000 U/kg)+G-CSF (250 µg/kg) injection, serum EPO levels in wild-type mice (C57BL/6 mice) increased significantly compared to control mice (each group n=6) (Fig. 4K). In contrast, G-CSF or EPO+G-CSF injection did not stimulate the additive upregulation of serum EPO in the Tg-HIF-1α mice (Fig. 4K).

Cellular apoptosis in ischemic rat brain slices was studied by TUNEL staining. Rats without MCA ligation had almost no TUNEL positive staining in their brain sections (each group n=8). The penumbral region surrounding the ischemic core of EPO+G-CSF-treated rats contained significantly fewer TUNEL positive cells than the same regions in EPO alone, G-CSF alone, or ischemic control (Fig. 4L).

EPO+G-CSF Enhanced Stem Cell Biological Activity

Bromodeoxyuridine (BrdU) labeling was used to trace the homing and engraftment of stem cells (including intrinsic neural
Plasticity Promote by HIF1α

A

B

C

D

E

HIF-1α EPO Actin

HIF-1α EPO Actin

G-CSF 2-ME2 -- + +

Control

G-CSF

G-CSF+ 2-ME2
progenitor cells [INPCs] and bone marrow derived stem cells [BMSCs] to brain tissue at 7 days after cerebral ischemia. According to cumulative BrdU labeling immunohistochemistry, many BrdU+ cells were found in the ipsilateral cortex near the infarct boundary (Fig. 5A, B and C) and the subventricular region of the ischemic hemisphere (Fig. 5D, E and F). BrdU+ cells were also identified around the lumen of blood vessels of varying calibers in the perivascular portion of the ischemic hemisphere (Fig. 5G, H and I). Results from BrdU pulse labeling experiments showed significantly greater numbers of BrdU+ cells were found in the ipsilateral cortex near the ischemic site, brain slices of the EPO+G-CSF-treated rats than those in EPO-, G-CSF-, or saline-treated rats (each group n=8) (Fig. 5J).

To assess specifically whether INPCs or BMSCs proliferated and differentiated into neural cells at ischemic sites, brain slices of GFP-chimeric and nestin-EGFP mice receiving each treatment type were examined by double-staining immunohistochemistry at 28 days after cerebral ischemia. In transgenic GFP-chimeric mice, more GFP+c-Kit+ BMSCs were dispersed over the right striatum, hippocampus and the penumbral area in EPO+G-CSF-treated mice compared to EPO-, G-CSF-, or saline-treated mice (each group n=8) (Fig. 5K). Fractions of GFP+c-Kit+ cells colocalizing with specific markers MAP-2, GFAP, Neu-N, and Musashi-1 in the EPO+G-CSF-treated mice (≈4%, ≈8%, ≈6%, and ≈5%, respectively), were significantly higher than those in the EPO-treated (≈2%, ≈5%, ≈4%, and ≈2%), G-CSF-treated (≈2%, ≈6%, ≈3%, and ≈3%) and control (≈1%, ≈0.5%, ≈1%, and ≈0.5%) groups (Fig. 5L). In nestin-EGFP mice, greater numbers of nestin-EGFP+ cells were also Ki67+ over the striatum and penumbral region in EPO+G-CSF-treated mice than in other treatment and control groups (each group n=8) (Fig. 5M). Quantitatively, fractions of nestin-EGFP+ cells colocalizing with Ki67 and the specific markers MAP-2, GFAP, and Neu-N were ≈2%, ≈3.5%, and ≈5% in the EPO+G-CSF-treated mice, respectively, significantly higher than in the EPO-treated (≈1.5%, ≈2%, and ≈3%), G-CSF-treated (≈1%, 1.8%, and 2.5%) and control (≈0.5%, ≈0.3%, and ≈0.5%) groups (Fig. 5N).

Discussion

Although many reports have noted the synergy between EPO and G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS) [16,18], investigators did not propose any mechanism to explain the results of clinical trial. In previous reports, both EPO and G-CSF have been shown to possess anti-apoptotic, angiogenic and neuroprotective properties [2,5,6] and have also been regarded as therapeutic agents in acute stroke models [1,19] and peripheral limb ischemic models [22]. In this study, we demonstrated that EPO in combination with G-CSF enhanced more plastic effects and revascularization in cerebral and limb ischemic models than either alone.

HIF-1α is activated by G-CSF in HUVECs under normoxia condition, as evidenced by our observation that G-CSF stimulation leads to enhanced HIF-1α activity and increased DNA-binding activity driven by the HRE. G-CSF is known to enhance the expression of two HIF-1α target genes, VEGF and SDF-1, in human neural stem cell cultures and platelets [22,23]. In our study, G-CSF also enhanced expression of the HIF-1α target gene EPO in HUVECs with a similar mechanism.

Cells express many proteins in response to hypoxia and ischemia, which supports cellular adaptation in response to altered metabolic demands and the removal of toxic substances [24]. As a master regulatory gene, HIF-1α controls critical pro-angiogenic genes such as VEGF and EPO [25,26]. Since VEGF and EPO genes contain the HRE in their promoter regions, some normoxic factors could also upregulate the expression of VEGF or EPO via HIF-1α activation [11,27]. According to two previous studies, G-CSF may promote VEGF secretion through HIF-1α activation [28,29]. Administration of G-CSF is known to augment angiogenesis by upregulation of VEGF in neurotrophils [29], and has been reported to raise serum VEGF level of patients [30].

Figure 1. G-CSF increased serum EPO in human and stimulated the expression of EPO by activating HIF-1α in HUVECs. (A) G-CSF treatment for 5 consecutive days in human showed significant increases serum EPO level compared to control [C]. (B–C) G-CSF induced the protein expression of both HIF-1α and EPO. (D) G-CSF also enhanced the activity of HIF-1α in cell lysate. The upregulation of HIF-1α activity, and protein expression of HIF-1α and EPO stimulated by adding G-CSF returned to normal levels after addition of 2-methoxyestradiol (2-ME2). (E) G-CSF treatment induced the translocation of HIF-1α into nuclei (Pl: propidium iodide, nuclear stain) or to perinuclear areas. In contrast, pretreatment with 2-ME2 inhibited the nuclear translocation of HIF-1α. Mean ± SEM, *P<0.05 and **P<0.01 vs. control. Bar = 50 μm.
A

EPO-HRE: GCCCTACGTGCTGTCTCA

B

1 2 3 4 5 6 7

Supershift
HIF-1α binding
Non-specific band

C

Luciferase activity (% of control)

|       | C    | OGD  | G-CSF | DFO  |
|-------|------|------|-------|------|
| pEpoE\-lac | 100  | 100  | 100   | 100  |
| pEpoF\-lac | 200  | 300  | 200   | 200  |
| pEpoEN\-lac | 150  | 150  | 150   | 150  |
| pEpoE\-lac | 300  | 300  | 300   | 300  |
| pEpoE\-lac | 250  | 250  | 250   | 250  |
| pEpoE\-lac | 200  | 200  | 200   | 200  |
Here we have demonstrated for the first time that G-CSF enhances the synthesis of EPO via upregulation of HIF-1α in primary cortical culture. The activated HIF-1α bound to the HRE of the EPO promoter and turned on the expression of EPO. The mechanism associated with EPO expression regulation and G-CSF in the present study may be similar to a previously described molecular mechanism involved in VEGF expression regulation and macrophage colony-stimulating factor (M-CSF) in cell monocytes and macrophages [29].

Recombinant EPO and G-CSF have been used clinically for over 20 years [31]. Many researchers have investigated the synergistic effects of administering EPO and G-CSF in hematopoiesis, including granulopoiesis and erythropoiesis [13,14,15]. Although either EPO or G-CSF has been shown to express neuroprotective and angiogenic effects in stroke animal models [1,6,19] and limb ischemia [22], no report has yet focused on the enhanced ability of these two cytokines in combination to induce neuroplasticity and angiogenesis. Other cytokines (stem cell factors, hepatocyte growth factors and stromal cell-derived factor 1α) in combination with G-CSF have also been reported as beneficial in animal stroke models [32,33] and limb ischemia [34]. We showed here that G-CSF and EPO synergized to produce better functional recovery from stroke and limb ischemia than either factor alone, which might be due to much enhanced angiogenesis and significant relevant neuroprotection. Since many cytokines and growth factors may be involved in ischemic repair and recovery mechanism, additional study is required to clarify which combination therapy might have the greatest plastic effect on ischemic tissue.

In the present study, the bone marrow stem cells (BMSCs) homing and differentiation were significantly enhanced by EPO in combination with G-CSF treatment. Previous investigators have also demonstrated the individual capability of EPO or G-CSF to stimulate proliferation and differentiation of neural stem/progenitor cells inside the animal brain [6,33,35,36,37,38,39]. Some studies discovered that EPO enhanced the expression of a signaling protein (SOCS2) and a transcriptional factor (neurogenin 1) to regulate the neural stem/progenitor cell proliferation and differentiation [35,37]. In other words, it is clear that both EPO and G-CSF are capable of stimulating neurogenesis to repair injured neural tissue. Other research teams have reported that a combination of G-CSF and stem cell factor (SCF) may be capable of inducing neural progenitor cell growth, thereby producing an enhanced plastic effect during brain repair [33,39]. Here we found that a combination of G-CSF and EPO could synergistically promote proliferation of the neural progenitor cells residing in the hippocampus and subventricular region of brain. In addition to BrdU labeling methods, we further applied the Nestin-EGFP transgenic mice model to certify the proliferation, differentiation and mobilization of endogenous neural progenitor cells in the ischemic brain after a combination of G-CSF and EPO treatment. In summary, EPO in combination with G-CSF might be a feasible therapeutic strategy to treat different neurodegenerative diseases.

Materials and Methods

Measurement of Serum EPO Levels in G-CSF-Treated Human Donors

We obtained serum samples from age-matched (Age = 35–40 y), healthy donors (male:female = 12:12, no athlete) at sequential time points (1, 3, 7 and 14 days) after subcutaneous G-CSF administration (10 to 15 μg/kg, Kirin) for 5 consecutive days according to the manufacturer’s instruction. All protocols and informed consents procedures were fully reviewed and approved by the Institutional Review Board of China Medical University Hospital. Informed consent was obtained from all participants. As a positive control, known level of EPO protein in serial dilution were measured using a human EPO ELISA kit (R&D Systems), with the results used to plot a standard curve. Each serum sample for EPO concentration measurement was run in triplicate and compared with the standard curve.

Cell Culture

Human umbilical vein endothelial cells (HUVECs; Cambrex) were cultured in EGM-2 medium containing human epidermal growth factor, hydrocortisone, human fibroblast growth factor, vascular endothelial growth factor, ascorbic acid, gentamicin, amphotericin-B, human insulin-like growth factor, heparin and 2% FBS at 37°C in a 5% CO2 humidified air incubator as previously described [40]. Confluent cells at passage 4 were used for all experiments.

ELISA Measurement of Activated HIF-1α in HUVECs

In order to evaluate the non-hypoxic activator effect of G-CSF, the levels of activated HIF-1α protein after G-CSF treatment were measured by ELISA. HUVECs were treated with different doses (0.01, 0.1, 1, and 10 μg/mL) of G-CSF (Kimy) for 6 hours. Nuclear extracts from these cells were incubated (50 μg/well) with biotinylated double-stranded oligonucleotide containing a consensus HIF-1α binding site from an active HIF-1α DuoSet IC ELISA kit (R&D Systems) according to the manufacturer’s instructions. The level of activated HIF-1α was measured by absorbance and was expressed as optical density (OD) at 450 nm–540 nm as previously described [41]. To confirm the role of HIF-1α in the upregulation of EPO by G-CSF on HUVECs, cells were pretreated with the HIF-1α inhibitor 2-ME2 (5 μM; Sigma) for 16 h as previously described [41]. Unless otherwise mentioned, experiments were performed in triplicate.

Western Blot and Immunocytochemical Analysis

HIF-1α and EPO expressions in HUVECs were measured by Western blot and immunohistochemical analyses. HUVECs were treated with 1 μg/mL G-CSF for different times (0.5, 1, 4, 12 and 24 hours), or treated with different concentrations of G-CSF ranging from 0.01 to 10 μg/mL for 6 hours. Western blot analyses of HIF-1α, and EPO expression from HUVECs were performed after each G-CSF treatment as previously described [42] using appropriately antibodies to HIF-1α (1:200; Novus Biologicals),
Plasticity Promote by HIF1α

A

Graph showing Caspase-3 activity (% of control) for E+G, E, G, and C conditions.

B

Western blot images for Bcl-2, Bcl-xL, Bax, Bad, and Actin under E+G, E, G, and C conditions.

C

Bar graphs showing BDNF (pg/ml) and SDF-1 (pg/ml) for E+G, E, G, and C conditions.
EPO (1:200; R&D Systems) and β-actin (1:2000; Santa Cruz Biotechnology).

For HIF-1α and EPO immunostaining, HUVECs were washed with PBS and fixed for 30 minutes at room temperature in 4% paraformaldehyde as previously described [42] using specific antibody against HIF-1α (1:200; Novus Biologicals) and EPO (1:200; R&D Systems) conjugated with FITC for 1 hour, and then rinsed 3 times in PBS. Finally, the slides were lightly counterstained with DAPI, washed with water, and then mounted.

To prepare cellular extracts for analysis, HUVECs were harvested and washed twice with cold phosphate-buffered saline (PBS). Nuclear and cytoplasm extracts were prepared using a commercial kit (Pierce). For oxygen glucose deprivation (OGD) treatment, cells were placed in a hypoxic chamber (Bug Box, Ruskinn Technology) for 4 hours, continuously flushed with 95% N2 and 5% CO2 at 37°C. For HIF-1α and EPO immunostaining, HUVECs were washed with PBS and fixed for 30 minutes at room temperature in 4% paraformaldehyde as previously described [42] using specific antibody against HIF-1α (1:200; Novus Biologicals) and EPO (1:200; R&D Systems) conjugated with FITC for 1 hour, and then rinsed 3 times in PBS. Finally, the slides were lightly counterstained with DAPI, washed with water, and then mounted.

Electrophoretic Mobility Shift Assay (EMSA)
Detailed protocols to assess HIF-1α DNA binding activity using EMSA have been described previously [44]. In this study we used a pair of oligonucleotide probes (5′-agcttGCCCTACGTGCTGTTCAC-3′ and 5′-aattcTGAGACAGCAGTAGGG Ca-3′) corresponding to the hypoxia-response element (HRE) in the EPO gene promoter [11]. Both oligonucleotides were non-radioisotope labeled using DIG Oligonucleotide 3′-End Labeling Kit (Roche). For supershift assays, 1 μg of anti-HIF-1α antibody (Novus Biologicals) was added to the samples 1 hour prior to the addition of labeled probes.

Transfection and Luciferase Reporter Assay
Luciferase assays and transient transfection of pEpoEm1-luc and pEpoE-luc reporter plasmids [a kind gift from Dr. LE Huang [44]] into HUVECs were performed as described previously [45].

In Vitro Primary Cortical Cultures (PCCs) Preparation and Oxygen Glucose Deprivation (OGD) Treatment
PCCs were prepared from the cerebral cortex of gestation day 17 embryos from Sprague-Dawley rats’ embryos (Animal Center, China Medical University, Taiwan) as described previously with modification [42]. In brief, PCCs were maintained under serum-free conditions in neurobasal medium (Invitrogen), supplemented with B-27 supplement (2% in Invitrogen), glutamine (0.5 mM; Sigma), glutamate (25 mM; Sigma), penicillin (100 U/ml) and streptomycin (100 µg/ml; Invitrogen Corp.). As suggested by the manufacturer, on day 4 half of the medium was removed and replaced with fresh medium without glutamate. The cultures were maintained in a humidified incubator at 37°C with 5% CO2. PCCs were used for experimentation on day 7. Regarding OGD treatment, cells cultured with glucose-free Earle’s balanced salt solution were placed in a hypoxic chamber for 4 hours (Bug Box, Ruskinn Technology) and continuously flushed with 95% N2 and 5% CO2 at 37°C to maintain a gas phase PO2 of <1 mmHg (OM-14 oxygen monitor; SensorMedics), and then reoxygenated for 24 hours.

Under OGD conditions, antiapoptotic proteins (Bcl-2, Bcl-xl) and proapoptotic proteins (Bax and Bad) from PCCs were analyzed after 12 hours of each cytokine pretreatment (G-CSF (2 µg/ml), EPO (10 U/ml), G-CSF (2 µg/ml), EPO (20 U/ml) (Amgen) or vehicle control) by Western blot as described previously [42]. On days 3-5 following each treatment, total amounts of BDNF, GDNF, SDF-1 and VEGF in the culture medium of PCCs were measured using a DuoSet IC ELISA kit (R&D Systems) according to the manufacturer’s instructions.

Measurement of Infarct Size Using Magnetic Resonance Image (MRI)
MRI (3.0 T, General Electric) was performed on rats in order to measure the infarct size after treatment of each group as described previously [42].

Neurological Behavioral Measurements
Behavioral assessments were performed 3 days before and 3, 7, 14 and 28 days after cerebral ischemia. The tests measured: (a) body asymmetry (b) locomotor activity, and (c) grip strength as previously described [42].

[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography (FDG-PET)
Experimental rats were examined using microPET scanning of [18F]fluoro-2-deoxyglucose (FDG) to measure relative metabolic activity by a protocol previously described [42].

Antia apoptotic Protein Analysis and ELISA for Growth Factors In Vivo
For Western blot analysis of apoptosis-related protein expression, experimental rats were anesthetized with chloral hydrate (0.4 g/kg, ip) at 24 hours after initiation of each treatment. Expression of apoptosis-related proteins (Bcl-2, Bcl-xl, Bad and Bag) in the right cortex and striatum region was also examined in each cytokine-treated and control rat [42]. In addition, ischemic cortical and striatal areas were evacuated on ice and immediately homogenized by a plastic homogenizer, and BDNF, GDNF, SDF-1 and VEGF protein levels were measured by ELISA as previously described with minor modification [46] according to the manufacturer’s instructions (DuoSet IC ELISA kit, R&D Systems). Optical density was measured using a spectrophotometer (Molecular Device Co).

Figure 3. EPO+G-CSF exerted an anti-apoptotic effect and enhanced neurotrophic factor synthesis in primary cortical cultures (PCCs). (A) Under OGD, PCCs pretreated with EPO+G-CSF (E+G) resulted in less caspase-3 activity than with EPO (E) or G-CSF (G) alone, or controls (C). (B) In a Western blot analysis, EPO+G-CSF-treated PCCs expressed more Bcl-2 than EPO, G-CSF or control groups. (C) Measurement of neurotrophic factors by ELISA revealed higher levels of BDNF and SDF-1 in the EPO+G-CSF-treated PCCs than in EPO- or G-CSF-treated cells or the control. Mean ± SEM, *P<0.05 and **P<0.01 vs. control.
doi:10.1371/journal.pone.0010093.g003
ELISA assays (Quantikine, R&D Systems) were used to measure EPO levels in blood samples 1, 3, 7, and 14 d following treatment with G-CSF or G-CSF plus EPO in wild type (C57BL/6) and TgCAGGCreERTM-HIF-1α+/f mice (Tg-HIF-1α+/f mice carrying a loxP-flanked allele of HIF-1α, a kind gift from Dr. Johnson [47]). The results were expressed as the net levels in the serum.

Terminal Deoxynucleotidyl Transferase-Mediated Digoxigenin-dUTP Nick-End Labeling (TUNEL) Histochemistry

Cellular apoptosis was assayed by histochemistry using a commercial TUNEL staining kit (DeadEnd Fluorimetric TUNEL system; Promega) as previously described [48].

Bromodeoxyuridine (BrdU) Labeling and Immunohistochemistry

BrdU (Sigma), a thymidine analog that is incorporated into the DNA of dividing cells during S-phase, was used to label cells undergoing mitotic division. Labeling protocol and BrdU immunostaining procedure have been described previously [42].

Construction of Transgenic Mice

In order to verify the enhancement of bone marrow stem cell (BMSC) and intrinsic neural progenitor cell (INPC) mobilization and homing into the infarcted brain following one of four treatments (EPO+G-CSF, EPO, G-CSF and vehicle), transgenic GFP-chimeric mice and nestin-GFP mice were built as

Figure 4. Administration of EPO+G-CSF to cerebral ischemic rats reduced infarct size and improved neurological function. (A) Experimental protocols for determining the best combinations of EPO and G-CSF to reduce infarct size. The dosage, combination and injection duration in each group are indicated in the white rectangles. The blue rectangles in each group represent non-treatment day-point after cytokine injections before euthanasia. In group E, EPO 5000 U/kg treatment started 30 minutes before stroke initiation. Group C (G-CSF alone), group D (EPO alone), group I (EPO+G-CSF) and saline-control group were selected for further study. (B) Representative MRI of ischemic rat brain: the white areas (white arrows) indicate the infarct zone in the right cerebral cortex on the 1st, 7th and 28th day after cerebral infarction. (C) Three formats of cerebral infarction assessment including total infarct volume, area of largest infarct section and number of infarct sections at the 7th day after cerebral ischemia were measured in rats treated with EPO+G-CSF (E+G) than in EPO (E) or G-CSF (G)-treated rats or the control (C) group. (D-G) Body asymmetry and locomotor activities after MCA ligation were measured in rats receiving EPO+G-CSF, EPO, G-CSF, and control saline from 7 to 28 days recovery. (H) Forelimb grip strength before and after ischemia were measured in rats receiving EPO+G-CSF, EPO, G-CSF, and control saline. (I) Representative TUNEL (green) and Hoechst 33342 (blue) co-staining images of cells death in right hemisphere of ischemic rat brains from EPO+G-CSF, EPO, G-CSF or control groups. Mean ± SEM, *P<0.05 and **P<0.01 vs. control. Bar = 50 μm.

doi:10.1371/journal.pone.0010093.g004
previously reported [49,50]. Starting one day after cerebral ischemia, BrdU immunoreactive cells were detected in the ipsilateral cortex near the infarct boundary (A–C, arrows), the subventricular area (D–F, arrows), and around blood vessels (G–I, arrows). (J) Numbers of BrdU immunoreactive cells were measured in the ipsilateral hemisphere of rats' brains treated with EPO+G-CSF (E+G), EPO (E), G-CSF (G) or controls (C). (K) GFP+ c-Kit+ bone marrow stem cells (BMSCs) in the peri-infarct and striatal areas (white arrows) were analyzed in transgenic GFP-chimeric mice treated with EPO+G-CSF (E+G), EPO (E), G-CSF (G) or controls. (L) In double immunofluorescent analysis (3D image), many GFP+ cells colocalized with specific markers GFAP, Neu-N, Musashi-1 and MAP-2. (M) Nestin-EGFP+ INPCs (white arrows) were stained for Ki67 in the penumbral region of nestin-EGFP mice treated with EPO+G-CSF (E+G), EPO (E), G-CSF (G) or controls. (N) Nestin-EGFP+Ki67+ cells also co-localized with specific markers MAP-2, GFAP, and Neu-N. Mean ± SEM, *P<0.05 and **P<0.01 vs. control. Bar = 50 μm.

doi:10.1371/journal.pone.0010093.g005

Figure 5. Subcutaneous administration of EPO+G-CSF enhanced the proliferation, differentiation and migration of stem cells in rats and mice. At one week after cerebral ischemia, BrdU immunoreactive cells were detected in the ipsilateral cortex near the infarct boundary (A–C, arrows), the subventricular area (D–F, arrows), and around blood vessels (G–I, arrows). (J) Numbers of BrdU immunoreactive cells were measured in the ipsilateral hemisphere of rats' brains treated with EPO+G-CSF (E+G), EPO (E), G-CSF (G) or controls (C). (K) GFP+ c-Kit+ bone marrow stem cells (BMSCs) in the peri-infarct and striatal areas (white arrows) were analyzed in transgenic GFP-chimeric mice treated with EPO+G-CSF (E+G), EPO (E), G-CSF (G) or controls. (L) In double immunofluorescent analysis (3D image), many GFP+ cells colocalized with specific markers GFAP, Neu-N, Musashi-1 and MAP-2. (M) Nestin-EGFP+ INPCs (white arrows) were stained for Ki67 in the penumbral region of nestin-EGFP mice treated with EPO+G-CSF (E+G), EPO (E), G-CSF (G) or controls. (N) Nestin-EGFP+Ki67+ cells also co-localized with specific markers MAP-2, GFAP, and Neu-N. Mean ± SEM, *P<0.05 and **P<0.01 vs. control. Bar = 50 μm.

doi:10.1371/journal.pone.0010093.g005

Laser-Scanning Confocal Microscopy for Double Immunofluorescence Analysis

The expression of cell type-specific markers in GFP+ cells was examined by double immunofluorescence using laser scanning confocal microscopy as previously described [42] with specific
antibodies against c-Kit (1:200; BD Pharmingen), GFAP (1:400; Sigma), MAP-2 (1:200; BM), nestin (1:400; Sigma), Neu-N (1:200; Chemicon), vWF (1:400; Sigma), Musashi-1 (1:300; Chemicon) and Ki67 (1:400; Novocastra Laboratories) conjugated with FITC (Sigma), MAP-2 (1:200; BM), nestin (1:400; Sigma), Neu-N (1:200; Chemicon) and CD31 immunohistochemical analysis as previously described [52].

Evaluation of Cerebral Angiogenesis
Cerebral microcirculation was analyzed by intravenous administration of the fluorescent plasma marker FITC-dextran (Sigma), and CD31 immunohistochemical analysis as previously described [42].

Measurement of Cerebral Blood Flow (CBF)
Rats anesthetized with chloral hydrate were positioned in a stereotaxic frame. Baseline local cortical blood flow (bCBF) was monitored with a laser doppler flowmeter (LDF monitor, Moore Instruments) as previously described [51]. In brief, CBF values were calculated as a percentage increase of bCBF.

Mouse Hindlimb Ischemia and Laser Doppler Imaging Analysis
Transgenic GFP-chimeric mice were anesthetized with chloral hydrate (0.4 g/kg, ip). The femoral artery ligation, limb blood flow measured by laser Doppler perfusion imaging (LDPH, Moore Instruments) and immunohistochemical studies were performed as previously described [52]. One day after arterial ligation, mice were randomly assigned to one of the four treatment groups: EPO (5000 U/kg)+G-CSF (250 μg/kg), G-CSF (250 μg/kg), EPO (10000 U/kg), and saline control.

Statistical Analysis
Observers were blind to the experimental conditions of each measurement. Results are expressed as mean ± SEM. The behavioral scores were evaluated for normality. We used one-way or two-way ANOVA with appropriate post hoc Newman-Keuls test to evaluate mean differences between different groups with different treatments. A value of P<0.05 was considered as significant.

Acknowledgments
We would like to thank Dr. H. Wilson and Ms. M. Loney of Academia Sinica of Taiwan for their critical reading of this manuscript.

Author Contributions
Conceived and designed the experiments: DDL SZL WCS. Performed the experiments: SPL WCS. Analyzed the data: SPL SDL DDS SZL WCS. Contributed reagents/materials/analysis tools: RSL WCS. Wrote the paper: SPL WCS.

References
1. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. (2004) Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35: 1732-1737.
2. Signore AP, Meng Z, Hastings T, Van Laar AD, Liang Q, et al. (2006) Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem 96: 423–443.
3. Brampton JE, Lee CR, Faukis D (1994) Fiblastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 48: 731–760.
4. Lee ST, Chu K, Jung KH, Ko SY, Kim EH, et al. (2005) Granulocyte colony-stimulating factor enhances angiogenesis after focal ischemia. Brain Res 1058: 120–128.
5. Park HK, Chu K, Lee ST, Jung KH, Kim EH, et al. (2005) Granulocyte colony-stimulating factor induces sensory motor recovery in intracerebral hemorrhage. Brain Res 1041: 125–131.
6. Schneider A, Kruger C, Strigel T, Weber D, Pitzer C, et al. (2005) The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115: 2083–2090.
7. Wenger RH (2000) Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 203: 1253–1263.
8. Dery MA, Michael MD, Richard DE. (2005) Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37: 515–540.
9. Helbing-Bargel T, Rutkowski K, Metzen E, Faundey J, Jellmann W (1999) Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561–1567.
10. Richard DE, Berra E, Poussegur J (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor alphal in vascular smooth muscle cells. J Biol Chem 275: 26765–26771.
11. Gotlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Robi U, et al. (2001) Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Cire Res 89: 47–54.
12. Dorozzo G, Russo I, Mattiello L, Riganati C, Anfossi G, et al. (2006) Insulin activates hypoxia-inducible factor-alpha in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia 49: 1049–1063.
13. de Haan G, Engel C, Donjte B, Nijhof W, Loeffler M (1994) Mutual inhibition of murine erythropoiesis and granulopoiesis during combined erythropoietin, granulocyte colony-stimulating factor, and stem cell factor administration in vivo interactions and dose-response surfaces. Blood 84: 4113–4143.
14. Roeder I, de Haan G, Engel C, Nijhof W, Donjte B, et al. (1998) Interactions of erythropoietin, granulocyte colony-stimulating factor, stem cell factor, and interleukin-11 on murine hematopoiesis during simultaneous administration. Blood 91: 3222–3229.
15. Ulrich TR, del Castillo J, McNeice IK, Yi ES, Alonso CP, et al. (1991) Stem cell factor in combination with granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF synergistically increases granulopoiesis in vivo. Blood 78: 1954–1962.
16. Caseyavall N, Durieux P, Du bois S, Hennery F, Lepage E, et al. (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104: 321–327.
17. Pierelli L, Imperio L, Greggi S, Salerno G, Panici PB, et al. (1999) Erythropoietin addition to granulocyte colony-stimulating factor augments life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 17: 1288.
18. Balleri E, Rossi E, Clavio M, Coniglio A, Gobbi M, et al. (2006) Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to promote hematopoiesis.
treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 85: 174–180.

Shyu WC, Lin SZ, Yang HI, Tzeng YS, Pang CY, et al. (2004) Functional recovery of stroke rats induced by granulocyte colony-stimulating factor-stimulated stem cells. Circulation 110: 1847–1854.

Spandou E, Papadopoulou Z, Soubasi V, Karkavelas G, Simeonidou C, et al. (2005) Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia-ischemia in rats. Brain Res 1045: 22–30.

Wei L, Han BH, Li Y, Keogh CL, Holtzman DM, et al. (2006) Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J Pharmacol Exp Ther 317: 109–116.

Jin DK, Shado K, Kopp HG, Freit I, Shmuelov SV, et al. (2006) Cytochrome-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangioeytes. Nat Med 12: 557–567.

Jung KH, Chu K, Lee ST, Kim SJ, Sinn DJ, et al. (2006) Granulocyte colony-stimulating factor stimulates neurogenesis via vascular endothelial growth factor with STAX activation. Brain Res 1073-1074: 190–201.

Xi X, Gai XY, Xie L, Zheng Q, Wei H, et al. (2005) BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor alpha1. Calcif Tissue Int 96: 1145–1151.

Shams I, Noe V, Avivi A (2005) Ontogenetic expression of erythropoietin and hypoxia-inducible factor-1 alpha genes in subterranean blind mole rats. FASEB J 19: 307–309.

Shweriki D, Birn A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845.

Kiriti K, Fox N, Komatsu N, Kauhasasky K (2005) Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1alpha. Blood 105: 4250–4263.

Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, et al. (2005) Granulocyte colony-stimulating factor promotes newecvascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 19: 2005–2007.

Varney ML, Olsen KJ, Mosley RL, Singh RK (2005) Paracrine regulation of vascular endothelial growth factor-a expression during macrophage-melanoma cell interaction: role of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res 25: 674–683.

Fuji K, Ishimaru F, Kozuka T, Matsu Y, Nakase K, et al. (2004) Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Br J Haematol 124: 190–194.

Bath PM, Sprigg N (2007) Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev: CD005207.

Ieda Y, Fujita J, Ieda M, Yagi T, Kawada H, et al. (2007) G-CSF and HGF: combination of vasculogenins and angiogenesis synergistically improves recovery in murine hind limb ischemia. J Mol Cell Cardiol 42: 540–548.

Kawada H, Takizawa S, Takanashi T, Morita Y, Fujita J, et al. (2006) Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 113: 701–710.

Tan Y, Zhao H, Eron D, Yang Z, Alonso-Diaz L, et al. (2007) Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor. Cardiovase Res 73: 823–832.

Schara Y, Hayashi T, Deguchi K, Zhang H, Tsuchiya A, et al. (2007) G-CSF enhances stem cell proliferation in rat hippocampus after transient middle cerebral artery occlusion. Neurosci Lett 418: 248–252.

Shigoto T, Sato M, Shimazaki T, Weiss S (2001) Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21: 9733–9743.

Wang L, Zhang Z, Zhang R, Hafner MS, Wong HK, et al. (2004) Erythropoietin up-regulates SOD2 in neuronal progenitor cells derived from SVZ of adult rat. Neuroreport 15: 1225–1229.

Wang L, Zhang ZG, Zhang RL, Jiao ZX, Wang Y, et al. (2006) Neurogenin 1 mediates erythropoietin enhanced differentiation of adult neuronal progenitor cells. J Cereb Blood Flow Metab 26: 536–564.

Zhao LR, Singhal S, Duan WM, Melita J, Keseler JA (2007) Brain repair by hematopoietic growth factors in a rat model of stroke. Stroke 38: 2584–2591.

Vescini L, Belloni D, Foglieni C, Cangi MG, Ferrari M, et al. (2007) Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the protospe inhibitor berotecumb. Blood 109: 2565–2570.

Dai Y, Xiu M, Wang Y, Pasha Z, Li T, et al. (2007) HIF-1alpha-induced VEGF overexpression in bone marrow stem cells protects cardomyocytes against ischemia. J Mol Cell Cardiol 42: 1036–1044.

Shyu WC, Lin SZ, Chiang MF, Chen DC, Su CY, et al. (2008) Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. J Clin Invest 118: 133–148.

Schioppa T, Unachhimog B, Saccani A, Biswas SK, Doni A, et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391–1402.

Huang LE, Pete EA, Schau M, Milligan J, Gu J (2002) Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway. J Biol Chem 277: 41750–41755.

Huang LE, Arany Z, Livingston DM, Bunn HF (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253–32259.

Franklin TB, Perrott-Sinal TS (2006) Sex and ovarian steroids modulate brain-derived neurotrophic factor (BDNF) protein levels in rat hippocampus under stressful and non-stressful conditions. Psychoneuroendocrinology 31: 38–48.

Ryan HE, Poloni M, McNulty W, Elen D, Gassmann M, et al. (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60: 4010–4015.

Li Y, Lu Z, Keogh CL, Yu SP, Wei L (2007) Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 27: 1043–1054.

Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, et al. (2002) Bone marrow as a source of endothelial cells and NeuExpressing cells after stroke. Stroke 33: 1362–1368.

Sawamoto K, Nakao N, Kakishita K, Ogawa Y, Toyama Y, et al. (2001) Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci 21: 3905–3903.

Park L, Ancraother J, Zhou P, Fryk K, Piotsk R, et al. (2005) NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 25: 1769–1777.

Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, et al. (2004) Local delivery of mouse-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109: 1545–1549.